RNAi Startup Solstice Biologics Whose Founder Was Shot By A Disgrunted Biotech Exec Just Raised $7.5 Million
Solstice Biologics, an interesting RNAi therapeutics company that has attracted attention for the wrong reasons, has raised $7.5 million, according to a regulatory filing, building on the $18 million raised last year from venBio and Aeris Capital. The San Francisco company is figuring out how to get RNAi-based drugs to cross multiple cell types to treat different kinds of tissues.
Less than 10% of the human genome is accessible to current drug discovery technologies. RNAi offers the promise of accessing the remaining 90% or more of the human genome.
Help employers find you! Check out all the jobs and post your resume.
Less than 10% of the human genome is accessible to current drug discovery technologies. RNAi offers the promise of accessing the remaining 90% or more of the human genome.
Help employers find you! Check out all the jobs and post your resume.